Free tool
FAERS Monitor: Karbinal Er
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022556 or its brand name (Karbinal Er, Carbinoxamine Maleate). Reports on generic versions are filed under their own applications.
Reports
157
Serious
77
49% of reports
Hospitalization
24
Death reported
29
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug toxicity14
- drug ineffective9
- headache9
- pain8
- pyrexia8
- dizziness7
- fatigue7
- sinusitis7
- unresponsive to stimuli7
- urticaria7
- vomiting7
- anxiety6
- cough6
- loss of consciousness6
- pruritus6
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2005 | 3 |
| 2006 | 6 |
| 2007 | 6 |
| 2008 | 6 |
| 2009 | 5 |
| 2010 | 4 |
| 2011 | 8 |
| 2012 | 6 |
| 2013 | 5 |
| 2014 | 5 |
| 2015 | 5 |
| 2016 | 9 |
| 2017 | 11 |
| 2018 | 12 |
| 2019 | 6 |
| 2020 | 5 |
| 2021 | 2 |
| 2022 | 15 |
| 2023 | 6 |
| 2024 | 8 |
| 2025 | 13 |
| 2026 | 11 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,002 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| drug toxicitySignal | 14 | 137.9 | 83.6 | 1,768 |
| unresponsive to stimuliSignal | 7 | 36.3 | 17.6 | 207 |
| sinusitisSignal | 7 | 9.2 | 4.4 | 43 |
| loss of consciousnessSignal | 6 | 6.3 | 2.9 | 22 |
| urticariaSignal | 7 | 5.6 | 2.7 | 22 |
| pyrexiaSignal | 8 | 3.1 | 1.6 | 10 |
| coughSignal | 6 | 2.9 | 1.3 | 6 |
| anxietySignal | 6 | 2.8 | 1.3 | 5 |
| pruritus | 6 | 2.1 | 1.0 | 2 |
| vomiting | 7 | 2.0 | 1.0 | 3 |
| headache | 9 | 1.9 | 1.0 | 3 |
| dizziness | 7 | 1.9 | 0.9 | 2 |
| pain | 8 | 1.7 | 0.9 | 2 |
| fatigue | 7 | 1.2 | 0.6 | 0 |
| drug ineffective | 9 | 0.9 | 0.5 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.